These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 21858223

  • 1. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
    Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, Ngan HY.
    PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
    Fan Q, Cai Q, Xu Y.
    Oncotarget; 2015 Sep 29; 6(29):27688-99. PubMed ID: 26299613
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma.
    Jiang L, Wang P, Chen H.
    Ups J Med Sci; 2014 Nov 29; 119(4):324-32. PubMed ID: 25231007
    [Abstract] [Full Text] [Related]

  • 5. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.
    Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K.
    Clin Cancer Res; 2014 Mar 15; 20(6):1477-88. PubMed ID: 24452790
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
    Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, Ali R, Sarkar FH.
    Breast Cancer Res Treat; 2010 Jul 15; 122(2):337-46. PubMed ID: 19813088
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.
    Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS.
    Am J Pathol; 2011 Feb 15; 178(2):537-47. PubMed ID: 21281787
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR.
    Oncotarget; 2015 Sep 29; 6(29):27613-27. PubMed ID: 26243836
    [Abstract] [Full Text] [Related]

  • 14. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
    Zhang X, Cheng L, Minn K, Madan R, Godwin AK, Shridhar V, Chien J.
    Oncotarget; 2014 Nov 30; 5(22):11365-80. PubMed ID: 25426548
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.
    Jiang L, Wang P, Chen L, Chen H.
    Int J Clin Exp Pathol; 2014 Nov 30; 7(9):5450-60. PubMed ID: 25337187
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.
    Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K.
    Cancer Res; 2013 Jul 01; 73(13):3987-96. PubMed ID: 23598278
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Gomes AR, Bella L, Khongkow P, Lam EW, Cheung AN.
    PLoS One; 2014 Jul 01; 9(11):e113478. PubMed ID: 25411964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.